Sanne L. Landman, Martijn J.W.E. Rabelink, Selas T.F. Bots, Yannick P.E. Lampo, Diana J.M. van den Wollenberg, Vera Kemp, Rob C. Hoeben
{"title":"A new adenovirus isolated from a western lowland gorilla held in captivity","authors":"Sanne L. Landman, Martijn J.W.E. Rabelink, Selas T.F. Bots, Yannick P.E. Lampo, Diana J.M. van den Wollenberg, Vera Kemp, Rob C. Hoeben","doi":"10.1016/j.virol.2025.110670","DOIUrl":null,"url":null,"abstract":"<div><div>Many adenovirus (AdV) species have been isolated from human and non-human primates. Here we describe the isolation of a new AdV from a western lowland gorilla held captive in a zoo. Analysis of the genome sequence demonstrated that this virus is a member of the Mastadenovirus genus, but markedly distinct from all previously described species. The new virus, AdV-lumc014, has a relatively low DNA sequence identity (<90 %) compared to other human and simian AdVs. The virus is most related to the HAdV-B and HAdV-E species, of which isolates were previously obtained from humans and apes (<em>i.e</em>. bonobos, chimpanzees, and western lowland gorillas). Phylogenetic analyses of the amino-acid sequences of the hexon, penton-base, fiber knob, protein IIIa, AdV polymerase, single-stranded DNA-binding protein, AdV protease, and protein IX confirmed the relationship with HAdV-B and HAdV-E. The phylogenetic distances exceed the value of 0.05 often used to separate distinct AdV species. In addition, we found evidence for recombination events between the AdV-lumc014 and HAdV-D. Almost no neutralizing immunity was detected in pooled human immunoglobulins, demonstrating that the virus is scarce or absent in the human population and that there is limited cross-reacting neutralizing immunity. This new AdV species may be a valuable expansion of the arsenal of AdVs that can be used for gene therapy, viral oncolysis, and as a vaccine carrier.</div></div>","PeriodicalId":23666,"journal":{"name":"Virology","volume":"612 ","pages":"Article 110670"},"PeriodicalIF":2.4000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0042682225002843","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Many adenovirus (AdV) species have been isolated from human and non-human primates. Here we describe the isolation of a new AdV from a western lowland gorilla held captive in a zoo. Analysis of the genome sequence demonstrated that this virus is a member of the Mastadenovirus genus, but markedly distinct from all previously described species. The new virus, AdV-lumc014, has a relatively low DNA sequence identity (<90 %) compared to other human and simian AdVs. The virus is most related to the HAdV-B and HAdV-E species, of which isolates were previously obtained from humans and apes (i.e. bonobos, chimpanzees, and western lowland gorillas). Phylogenetic analyses of the amino-acid sequences of the hexon, penton-base, fiber knob, protein IIIa, AdV polymerase, single-stranded DNA-binding protein, AdV protease, and protein IX confirmed the relationship with HAdV-B and HAdV-E. The phylogenetic distances exceed the value of 0.05 often used to separate distinct AdV species. In addition, we found evidence for recombination events between the AdV-lumc014 and HAdV-D. Almost no neutralizing immunity was detected in pooled human immunoglobulins, demonstrating that the virus is scarce or absent in the human population and that there is limited cross-reacting neutralizing immunity. This new AdV species may be a valuable expansion of the arsenal of AdVs that can be used for gene therapy, viral oncolysis, and as a vaccine carrier.
期刊介绍:
Launched in 1955, Virology is a broad and inclusive journal that welcomes submissions on all aspects of virology including plant, animal, microbial and human viruses. The journal publishes basic research as well as pre-clinical and clinical studies of vaccines, anti-viral drugs and their development, anti-viral therapies, and computational studies of virus infections. Any submission that is of broad interest to the community of virologists/vaccinologists and reporting scientifically accurate and valuable research will be considered for publication, including negative findings and multidisciplinary work.Virology is open to reviews, research manuscripts, short communication, registered reports as well as follow-up manuscripts.